Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.06
VSCI's Cash to Debt is ranked lower than
56% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. VSCI: 0.06 )
VSCI' s 10-Year Cash to Debt Range
Min: 0.05   Max: 22796
Current: 0.06

0.05
22796
Equity to Asset -1.76
VSCI's Equity to Asset is ranked lower than
57% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. VSCI: -1.76 )
VSCI' s 10-Year Equity to Asset Range
Min: -1.76   Max: 0.93
Current: -1.76

-1.76
0.93
F-Score: 2
Z-Score: -15.98
M-Score: -6.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -40.87
VSCI's Operating margin (%) is ranked higher than
56% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. VSCI: -40.87 )
VSCI' s 10-Year Operating margin (%) Range
Min: -158.06   Max: -16.27
Current: -40.87

-158.06
-16.27
Net-margin (%) -43.10
VSCI's Net-margin (%) is ranked higher than
56% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. VSCI: -43.10 )
VSCI' s 10-Year Net-margin (%) Range
Min: -151.61   Max: 212
Current: -43.1

-151.61
212
ROA (%) -69.91
VSCI's ROA (%) is ranked higher than
50% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. VSCI: -69.91 )
VSCI' s 10-Year ROA (%) Range
Min: -88.06   Max: 90.36
Current: -69.91

-88.06
90.36
ROC (Joel Greenblatt) (%) -106.84
VSCI's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. VSCI: -106.84 )
VSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -478.99   Max: -94.97
Current: -106.84

-478.99
-94.97
Revenue Growth (3Y)(%) 9.70
VSCI's Revenue Growth (3Y)(%) is ranked higher than
84% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. VSCI: 9.70 )
VSCI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -17.4   Max: 10.1
Current: 9.7

-17.4
10.1
EBITDA Growth (3Y)(%) -18.80
VSCI's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. VSCI: -18.80 )
VSCI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54   Max: 54.9
Current: -18.8

-54
54.9
EPS Growth (3Y)(%) -18.10
VSCI's EPS Growth (3Y)(%) is ranked higher than
67% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. VSCI: -18.10 )
VSCI' s 10-Year EPS Growth (3Y)(%) Range
Min: -47.7   Max: 48.1
Current: -18.1

-47.7
48.1
» VSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

VSCI Guru Trades in Q4 2013

Jim Simons 70,000 sh (-12.83%)
» More
Q1 2014

VSCI Guru Trades in Q1 2014

Jim Simons 67,700 sh (-3.29%)
» More
Q2 2014

VSCI Guru Trades in Q2 2014

Jim Simons 53,300 sh (-21.27%)
» More
Q3 2014

VSCI Guru Trades in Q3 2014

Jim Simons 48,100 sh (-9.76%)
» More
» Details

Insider Trades

Latest Guru Trades with VSCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 2.05
VSCI's P/S is ranked higher than
74% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. VSCI: 2.05 )
VSCI' s 10-Year P/S Range
Min: 2.14   Max: 21.25
Current: 2.05

2.14
21.25
EV-to-EBIT -8.52
VSCI's EV-to-EBIT is ranked higher than
55% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. VSCI: -8.52 )
VSCI' s 10-Year EV-to-EBIT Range
Min: -36.6   Max: -1.6
Current: -8.52

-36.6
-1.6
Current Ratio 2.89
VSCI's Current Ratio is ranked higher than
72% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. VSCI: 2.89 )
VSCI' s 10-Year Current Ratio Range
Min: 1.26   Max: 13.88
Current: 2.89

1.26
13.88
Quick Ratio 1.54
VSCI's Quick Ratio is ranked higher than
65% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. VSCI: 1.54 )
VSCI' s 10-Year Quick Ratio Range
Min: 0.42   Max: 12.55
Current: 1.54

0.42
12.55

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.41
VSCI's Price/Median PS Value is ranked higher than
95% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. VSCI: 0.41 )
VSCI' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 2.85
Current: 0.41

0.39
2.85
Earnings Yield (Greenblatt) -11.70
VSCI's Earnings Yield (Greenblatt) is ranked higher than
54% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. VSCI: -11.70 )
VSCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -11.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Vision-Sciences Inc was incorporated in Delaware, and are the successor to operations originally begun in 1987. The Company designs, develops, manufactures, and markets products for endoscopy. Its products include flexible endoscope and borescopes. Its segments include medical and industrial. Its medical segment designs, manufactures and sells endoscopy-based products, including its flexible endoscopes, and its EndoSheath technology referred to as a sheath or EndoSheath disposable, for a variety of specialties and markets. Its industrial segment, through its wholly-owned subsidiary Machida, designs, manufactures, and sells borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers or a small camera for the visual inspection of narrow cavities. Its borescopes are used to inspect aircraft engines, cast parts and ground turbines, among other items. The Companys products are sold throughout the world through direct sales representatives in the United States (U.S.) and independent distributors for the rest of the world. The Company owns the registered trademarks Vision Sciences, Slide-On, EndoSheath, EndoWipe and The Vision System. Its competitors include Olympus, Lenox, Pentax, and Karl Storz. Its operations are regulated under various federal, state, and local laws governing the environment, including laws governing the discharge of pollutants into the air and water, the management and disposal of hazardous substances and wastes, and the clean-up of contaminated sites.
» More Articles for VSCI

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 09 2011 
VisionSciences Inc. Reports Operating Results (10-Q) Nov 10 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Aug 11 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Nov 12 2009 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 13 2009 

More From Other Websites
UPI SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of... Dec 23 2014
UROPLASTY, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Dec 22 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Dec 22 2014
Uroplasty and Vision-Sciences to Merge, Creating Innovative Medical Device Company Positioned for... Dec 22 2014
Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth Dec 22 2014
Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth Dec 22 2014
Uroplasty and Vision-Sciences to Merge, Creating Innovative Medical Device Company Positioned for... Dec 22 2014
GERD Awareness Week Puts the Focus on Patient-Centric Diagnostics Nov 25 2014
GERD Awareness Week Puts the Focus on Patient-Centric Diagnostics Nov 25 2014
VISION SCIENCES INC /DE/ Financials Nov 21 2014
10-Q for Vision-Sciences, Inc. Nov 15 2014
VISION SCIENCES INC /DE/ Files SEC form 10-Q, Quarterly Report Nov 13 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 05 2014
Vision-Sciences Reports Financial Results of Second Quarter and First Half Fiscal 2015 Nov 05 2014
Q2 2015 Vision Sciences Inc Earnings Release - After Market Close Nov 05 2014
Study Reveals Endoscopes May Be Susceptible to Inadequate Sterilization Despite Following... Nov 04 2014
Vision-Sciences to Host Second Quarter Fiscal 2015 Results Call Oct 29 2014
Vision-Sciences TNE System Offers Solution for Sedation Concerns Oct 27 2014
Vision-Sciences TNE System Offers Solution for Sedation Concerns Oct 27 2014
Vision-Sciences Announces CE Mark and European Launch of Next Generation EndoSheath(R) Bronchoscopy... Oct 01 2014
VISION SCIENCES INC /DE/ Files SEC form 10-Q, Quarterly Report Aug 14 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 05 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Aug 01 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Other Events Jul 08 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Jun 27 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jun 17 2014
Vision-Sciences to Discuss EndoSheath(R) Technology on "Taking Stock with Pimm Fox" Mar 17 2014
Vision-Sciences to Present at BTIG's Inaugural Snowbird Medical Technology and Diagnostics... Mar 13 2014
Patient Safety Awareness Week Brings Awareness to Health Care-Acquired Infection Mar 04 2014
Vision-Sciences Announces Revenue of $4.5 Million for Third Quarter and $12.1 Million for First Nine... Feb 03 2014
Vision-Sciences to Host Third Quarter Fiscal 2014 Results Call Jan 24 2014
Vision-Sciences' EndoSheath(R) Technology Offers Patented Solution to "Nightmare Bacteria" Jan 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK